Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
EYPT 
Eyepoint Pharmaceuticals Inc (EYPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: EYPT (5-star) is a STRONG-BUY. BUY since 13 days. Simulated Profits (11.81%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $35.5
1 Year Target Price $35.5
| 9 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 384.54% | Avg. Invested days 47 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.33B USD | Price to earnings Ratio - | 1Y Target Price 35.5 |
Price to earnings Ratio - | 1Y Target Price 35.5 | ||
Volume (30-day avg) 13 | Beta 1.69 | 52 Weeks Range 3.91 - 19.11 | Updated Date 12/11/2025 |
52 Weeks Range 3.91 - 19.11 | Updated Date 12/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6420.81% |
Management Effectiveness
Return on Assets (TTM) -49.39% | Return on Equity (TTM) -98.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1201481318 | Price to Sales(TTM) 31.48 |
Enterprise Value 1201481318 | Price to Sales(TTM) 31.48 | ||
Enterprise Value to Revenue 28.38 | Enterprise Value to EBITDA -11.49 | Shares Outstanding 82787220 | Shares Floating 61988587 |
Shares Outstanding 82787220 | Shares Floating 61988587 | ||
Percent Insiders 2.89 | Percent Institutions 86.69 |
Upturn AI SWOT
Eyepoint Pharmaceuticals Inc
Company Overview
History and Background
EyePoint Pharmaceuticals, Inc. was founded in 1994 and was formerly known as pSivida Corp. The company rebranded to EyePoint Pharmaceuticals in 2017 to better reflect its focus on ophthalmic drug delivery. Significant milestones include the development and FDA approval of its first product, ILUVIEN, and subsequent approvals for YUTIQ and DEXYCU.
Core Business Areas
- Ophthalmic Pharmaceuticals: EyePoint Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of innovative ophthalmic products, primarily addressing diseases of the back of the eye.
Leadership and Structure
The leadership team typically includes a Chief Executive Officer, Chief Medical Officer, Chief Commercial Officer, and a board of directors. The organizational structure is focused on research and development, clinical trials, regulatory affairs, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- ILUVIEN: A sustained-release intravitreal implant for the treatment of diabetic macular edema (DME) and posterior uveitis. Market share data is not publicly disclosed but it competes with other DME treatments like anti-VEGF injections (e.g., Eylea, Lucentis) and other sustained-release options. Key competitors include Regeneron Pharmaceuticals, Novartis, and Roche.
- YUTIQ: A sustained-release intravitreal implant for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Similar to ILUVIEN, specific market share figures are not readily available, and it competes within the uveitis treatment landscape against systemic immunosuppressants and other intravitreal therapies. Competitors include various pharmaceutical companies with ophthalmic portfolios.
- DEXYCU: An intracameral, extended-release formulation of dexamethasone for the treatment of postoperative inflammation and pain following ocular surgery. This product competes in the post-operative eye care market. Competitors include topical corticosteroids and other intracameral solutions.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical market is driven by an aging population, increasing prevalence of eye diseases like AMD, DME, and uveitis, and advancements in drug delivery technologies. The market is highly competitive, with significant investment in R&D for novel treatments and improved patient outcomes.
Positioning
EyePoint Pharmaceuticals is positioned as a niche player focusing on sustained-release drug delivery for complex ophthalmic conditions, particularly those affecting the posterior segment of the eye. Its competitive advantage lies in its proprietary drug delivery technology and its portfolio of approved products addressing unmet needs.
Total Addressable Market (TAM)
The TAM for ophthalmology is substantial, with specific segments like DME, uveitis, and post-operative care representing billions of dollars globally. EyePoint Pharmaceuticals is positioned to capture a portion of this TAM through its specialized products, though its current market share is limited compared to broader ophthalmic players.
Upturn SWOT Analysis
Strengths
- Proprietary sustained-release drug delivery technology.
- Approved and commercially available products (ILUVIEN, YUTIQ, DEXYCU).
- Focus on unmet needs in the posterior segment of the eye.
- Experienced management team with pharmaceutical industry expertise.
Weaknesses
- Limited product pipeline compared to larger pharmaceutical companies.
- Reliance on a few key products for revenue.
- Potential for significant R&D costs and clinical trial failures.
- Competition from established players with larger resources.
Opportunities
- Expansion of existing product indications and geographies.
- Development of new drug delivery platforms or formulations.
- Strategic partnerships or collaborations for pipeline advancement or commercialization.
- Increasing prevalence of target eye diseases.
Threats
- Intense competition from both large and small pharmaceutical companies.
- Pricing pressures and reimbursement challenges.
- Regulatory hurdles and potential delays in product approvals.
- Patent expirations and the emergence of generic competition.
- Adverse events or safety concerns related to products.
Competitors and Market Share
Key Competitors
- Regeneron Pharmaceuticals (REGN)
- Novartis AG (NVS)
- Roche Holding AG (RHHBY)
- Allergan (now part of AbbVie - ABBV)
Competitive Landscape
EyePoint's advantage lies in its specialized sustained-release technology, particularly for posterior segment eye diseases. However, competitors like Regeneron and Novartis have broader portfolios and significantly larger R&D budgets, allowing them to invest in a wider array of therapeutic areas and potentially develop competing or superior delivery systems. AbbVie, through Allergan, also holds a strong position in ophthalmology.
Growth Trajectory and Initiatives
Historical Growth: Historically, EyePoint's growth has been tied to the development and commercialization of its core products. Revenue has been increasing as these products gain market traction. However, the company has also experienced periods of net losses due to significant investment in R&D and commercial infrastructure.
Future Projections: Future growth projections are typically based on analyst estimates of product sales, market penetration, and potential new product launches or approvals. Expansion into new markets and indications are key drivers.
Recent Initiatives: Recent initiatives likely include efforts to expand the commercial reach of ILUVIEN, YUTIQ, and DEXYCU, explore new clinical applications, and potentially advance other pipeline candidates.
Summary
EyePoint Pharmaceuticals has established itself in the ophthalmic space with key sustained-release products like ILUVIEN and YUTIQ. Its proprietary technology provides a competitive edge in treating chronic eye diseases. However, the company faces strong competition from larger pharmaceutical giants and must navigate significant R&D investments and market access challenges to achieve sustained profitability and growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations websites
- SEC Filings (10-K, 10-Q)
- Industry Market Research Reports
- Financial News Outlets
Disclaimers:
This JSON output is a compilation of publicly available information and AI-driven analysis. It is intended for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share data is estimated and may vary across different reports. Financial performance figures are subject to change with new filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eyepoint Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2005-01-27 | President, CEO & Director Dr. Jay S. Duker M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 165 | Website https://eyepoint.bio |
Full time employees 165 | Website https://eyepoint.bio | ||
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.